Kite, A Gilead Company, Announces Results From Phase 2 ALYCANTE Study Of Yescarta® CAR T-Cell Therapy For R/R Large B-cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Kite, a Gilead Company, has announced results from its Phase 2 ALYCANTE study of Yescarta CAR T-Cell Therapy for R/R Large B-cell Lymphoma. The results are promising and could potentially lead to a new treatment option for patients.
September 18, 2023 | 8:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The announcement of promising results from Kite's Phase 2 study of Yescarta CAR T-Cell Therapy could potentially boost Gilead's stock in the short term.
The announcement of positive results from a Phase 2 study is typically seen as a positive development for a pharmaceutical company. This could lead to increased investor confidence in Gilead, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100